Vivus Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VIVUS LLC, and what generic alternatives to VIVUS LLC drugs are available?
VIVUS LLC has one approved drug.
There are six US patents protecting VIVUS LLC drugs.
There are thirty-eight patent family members on VIVUS LLC drugs in seventeen countries and three supplementary protection certificates in two countries.
Drugs and US Patents for Vivus Llc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-003 | Jul 17, 2012 | AB | RX | Yes | No | 8,580,299 | ⤷ Sign Up | ⤷ Sign Up | |||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-004 | Jul 17, 2012 | AB | RX | Yes | Yes | 8,895,058 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-001 | Jul 17, 2012 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ||||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-004 | Jul 17, 2012 | AB | RX | Yes | Yes | 9,011,905 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-001 | Jul 17, 2012 | AB | RX | Yes | No | 8,580,298 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-002 | Jul 17, 2012 | AB | RX | Yes | No | 9,011,905 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Vivus Llc | QSYMIA | phentermine hydrochloride; topiramate | CAPSULE, EXTENDED RELEASE;ORAL | 022580-002 | Jul 17, 2012 | AB | RX | Yes | No | 8,580,298 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Vivus Llc
Paragraph IV (Patent) Challenges for VIVUS LLC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Capsules | 3.75 mg/23 mg, 7.5 mg/46 mg, 11.25 mg/69 mg, 15 mg/92 mg | ➤ Subscribe | 2013-07-18 |
International Patents for Vivus Llc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Cyprus | 1118103 | ⤷ Sign Up |
Mexico | 342684 | ⤷ Sign Up |
South Africa | 201008839 | ⤷ Sign Up |
Japan | 2011522896 | ⤷ Sign Up |
Japan | 2011522897 | ⤷ Sign Up |
Japan | 2017105788 | ⤷ Sign Up |
Mexico | 2010013505 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Vivus Llc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2317997 | CR 2021 00049 | Denmark | ⤷ Sign Up | PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212 |
2317997 | 2190050-1 | Sweden | ⤷ Sign Up | PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212 |
2317997 | CA 2021 00049 | Denmark | ⤷ Sign Up | PRODUCT NAME: PHENTERMIN OG TOPIRAMAT; NAT. REG. NO/DATE: 63166, 63167, 63168, 63169 20210705; FIRST REG. NO/DATE: IS IS/1/21/018/01-04 20210212 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.